New Biomarker Offers Hope for Understanding Fragile X Syndrome
A simple blood test could soon offer families a clearer understanding of the challenges and potential developmental trajectory of children diagnosed with Fragile X syndrome (FXS), the moast common inherited cause of intellectual disability in the United States. Thousands are diagnosed with the condition each year, frequently enough leaving families unprepared for the complexities ahead.
Currently, while the genetic cause – a mutation in the FMR1 gene – is known, predicting the severity of intellectual and developmental disabilities remains a meaningful challenge. Existing tests can identify the condition, but provide limited guidance to parents navigating their child’s future.
Researchers at the University of Sherbrooke in Quebec are working to change that. A team led by Asma Laroui Artuela Çaku and Jean-Francois Lepage has identified a potential biomarker that correlates with the severity of FXS symptoms, offering a less invasive way to assess brain function. Their findings were recently published in the Journal of Lipid Research.
“We have access to the FXS clinic,which regroups patients from all around the province,so we can do a lot of associations between the lipid profile and the clinical phenotype,” a lead researcher explained.
The team’s breakthrough centers on 24S-hydroxycholesterol, or 24-OHC, a metabolite of brain cholesterol. They discovered that levels of 24-OHC were substantially lower in patients with FXS compared to control groups. This is significant as cholesterol is synthesized in the brain by astrocytes, and excess cholesterol is converted into 24-OHC before circulating throughout the body. Therefore, a decrease in 24-OHC levels in the blood may indicate disruptions in brain cholesterol metabolism.
Further investigation revealed a strong correlation between 24-OHC levels and neurological function. Patients with lower 24-OHC levels exhibited slower motor evoked potentials – a measure of how efficiently motor neurons fire when stimulated – indicating impaired neurological signaling. Behavioral and cognitive assessments also showed that lower 24-OHC levels were associated with increased difficulties in social communication, as well as heightened symptoms of anxiety and depression.
These findings suggest that 24-OHC could serve as a valuable tool for clinicians, providing families with a more informed outlook following an FXS diagnosis. “We try to develop techniques that are not invasive,” a researcher stated. “In a simple blood collection, you can have information about the brain.” This non-invasive approach offers a significant advantage over more complex and possibly stressful diagnostic procedures.
The research also expands our understanding of brain cholesterol biology, a field that has historically received less attention than peripheral cholesterol studies. “There is a lot of research from the peripheral, but comparatively fewer studies on brain cholesterol,” one researcher noted. “Though, we found that in diseases where brain cholesterol is dysregulated, this imbalance can affect the phenotype. We are giving importance to research on brain cholesterol.”
The team is now focused on pinpointing the underlying cause of the abnormal cholesterol metabolism observed in FXS patients. “Maybe it’s the enzyme that’s dysregulated, or maybe the astrocytes cannot produce enough cholesterol,” a researcher speculated.
Despite the remaining questions, the researchers are optimistic that their work will pave the way for earlier interventions and improved care for individuals with Fragile X syndrome.
